A composite prognostic model for overall survival (OS) based on residual cancer burden (RCB) and tumor-infiltrating lymphocytes (TILs) on residual disease (RCB+TIL) in HER2+ breast cancer patients treated with neoadjuvant therapy: a multicenter studyFederica Miglietta, M.V. Dieci, M. Ragazzi et al.|European Journal of Cancer|2022Cited by 0
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trialCharles M. Perou, Ana Vivancos, A Prat et al.|UNC Libraries|2024Cited by 0